Skip to content

Monopar Therapeutics MNPR Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$14.98M-9.2%-$13.72M+29.4%-$19.44M-12.3%-$17.31M-4.5%-$16.57M-6.3%
$5.18M+7.0%$4.84M+20.6%$4.01M+28.9%$3.11M+43.6%$2.17M+90.0%
-$10.01M+17.9%-$12.2M-12.7%-$10.83M-10.4%-$9.81M+5.8%-$10.41M-62.6%
-$68.71M-8.3%-$63.45M-307%-$15.6M-24.9%-$12.49M+8.7%-$13.68M+4.6%
$91.87M-0.1%$91.96M-37.9%$148.1M
$121.66M+264%$33.38M+4.6%$31.9M-17.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monopar Therapeutics generate?
Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
Where does Monopar Therapeutics's cash flow data come from?
Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.